Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Diovan®
( valsartan )Cardiovascular, Renal and Metabolism -
Diovan HCT® /Co-Diovan®
( valsartan, hydrochlorothiazide )Cardiovascular, Renal and Metabolism -
Desferal®
Available in -
Cosentyx®
( secukinumab )Immunology and Dermatology -
Comtan®
( entacapone )Neuroscience -
Coartem ®
Available in -
Ciprodex®
( ciprofloxacin, dexamethasone )OphthalmologyAvailable in -
Betoptic S®
Available in -
Beovu®
( brolucizumab )Ophthalmology